Key Details
Price
$7.48Annual Revenue
$1.19 MAnnual ROE
-81.91%Beta
2.12Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Sept 26, 2013Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
SAN CARLOS, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on December 19, 2024 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 203,980 shares of Iovance's common stock to forty-eight new, non-executive employees.
Investors are fortunate to have access to a universe of stocks that they can buy or sell at any given time. Sometimes, however, limiting your options can be a powerful exercise.
It's usually not difficult to find a compelling growth stock to step into. Choosing a growth stock you're confident holding onto for a decade or more, however, is a different story.
As the rising star of cell therapy biotechs, Iovance Biotherapeutics (IOVA 3.76%) is a hot stock that's capturing a lot of attention, and for good reason. Iovance's one-of-a-kind medicine is already selling like hotcakes, and there's reason to believe that plenty more growth is on the way.
Iovance Biotherapeutics' Q3 earnings outperformed expectations, with $58.6m in revenue, but shares fell due to high market expectations and competition concerns. Amtagvi, Iovance's lead drug, shows strong commercial potential with 2025 revenue guidance of $450-$475m and significant opportunities in melanoma and other cancers including NSCLC. Despite high cash burn and competition, Iovance's growth in revenue, reimbursement, and treatment centers suggests a “buy the dip” opportunity for risk-tolerant investors.
Iovance reports better-than-expected third-quarter results. Management maintains its previously issued guidance for product revenues for full-year 2024 and 2025.
Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.46 per share a year ago.
SAN CARLOS, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its third quarter and year to date 2024 financial results on Thursday, November 7, 2024.
With a cutting-edge melanoma drug now on the market, the company is positioned for a breakout.
The biotech is making important breakthroughs, but is that enough?
FAQ
- What is the primary business of Iovance Biotherapeutics?
- What is the ticker symbol for Iovance Biotherapeutics?
- Does Iovance Biotherapeutics pay dividends?
- What sector is Iovance Biotherapeutics in?
- What industry is Iovance Biotherapeutics in?
- What country is Iovance Biotherapeutics based in?
- When did Iovance Biotherapeutics go public?
- Is Iovance Biotherapeutics in the S&P 500?
- Is Iovance Biotherapeutics in the NASDAQ 100?
- Is Iovance Biotherapeutics in the Dow Jones?
- When was Iovance Biotherapeutics's last earnings report?
- When does Iovance Biotherapeutics report earnings?
- Should I buy Iovance Biotherapeutics stock now?